AR
KNSA icon

Advisory Research’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Advisory Research’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-65,450
Closed -$1.15M – 245
2023
Q4 		$1.15M Sell
65,450
-138,648
-68% -$2.28M 0.18% 145
2023
Q3 		$3.55M Buy
204,098
+173,546
+568% +$2.92M 0.49% 48
2023
Q2 		$430K Sell
30,552
-1,322
-4% -$17.7K 0.06% 310
2023
Q1 		$343K Hold
31,874
– – 0.06% 279
2022
Q4 		$477K Buy
+31,874
New +$464K 0.04% 254

Other funds holding KNSA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Advisory Research's KNSA Position: Q1 2024 in Review

Advisory Research sold out of Kiniksa Pharmaceuticals (KNSA) in Q1 2024, closing a stake of 65,450 shares — an estimated $1.15M sold.

Advisory Research first reported a position in KNSA in Q4 2022 and held it in 5 quarters. The position peaked at $3.55M in Q3 2023. 154 funds tracked by Wall St. Rank hold KNSA as of Q1 2024.

  • Advisory Research reported no remaining Kiniksa Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Advisory Research sold 65,450 Kiniksa Pharmaceuticals shares in Q1 2024, an estimated $1.15M.
  • Advisory Research first reported a position in Kiniksa Pharmaceuticals in Q4 2022 and held it in 5 quarters.
  • Advisory Research's Kiniksa Pharmaceuticals position peaked at $3.55M in Q3 2023.
  • 154 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2024.

Based on Advisory Research's 13F filing for Q1 2024, filed 14 May 2024.